Protein Therapeutics Production: Large-scale Mammalian Cell Culture - Biologics Market Research

Protein Therapeutics Production: Large-scale Mammalian Cell Culture
Drug and Market Development Publishing
December 5, 2005
75 Pages
Pub ID: DSMD1197163
US $795.00 Online Download
US $795.00 Hard Copy Mail Delivery

Abstract
D&MD's Protein Therapeutics Production: Large-scale Mammalian Cell Culture provides an introduction and overview of current manufacturing practices associated with large scale mammalian cell culture. The focus is on the use of large scale mammalian cell culture systems. The industry, which began in the late 1980s from the utilization of recombinant DNA technology and cell hybridization, is now a significant production process of the biopharmaceutical industry. As of 2003 the biopharmaceutical market represented over $40 billion in sales annually contributed by over 90 products approved for 130 disease indications. With over 350 additional products in clinical development and approximately 10 new products approved per year, growth for this market is expected to continue at >20% annually. Today, a quarter of all new drug approvals are for biopharmaceuticals. The approved drugs include hormones, blood factors, thrombolytics, vaccines, interferons, monoclonal antibodies (MAb), and therapeutic enzymes. The primary method of producing many of these biopharmaceuticals is mammalian cell culture. This publication presents an overview of current techniques used for the production of protein therapeutics.